Literature DB >> 23728178

C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation.

Agustín Tortajada1, Hugo Yébenes, Cynthia Abarrategui-Garrido, Jaouad Anter, Jesús M García-Fernández, Rubén Martínez-Barricarte, María Alba-Domínguez, Talat H Malik, Rafael Bedoya, Rocío Cabrera Pérez, Margarita López Trascasa, Matthew C Pickering, Claire L Harris, Pilar Sánchez-Corral, Oscar Llorca, Santiago Rodríguez de Córdoba.   

Abstract

C3 glomerulopathies (C3G) are a group of severe renal diseases with distinct patterns of glomerular inflammation and C3 deposition caused by complement dysregulation. Here we report the identification of a familial C3G-associated genomic mutation in the gene complement factor H–related 1 (CFHR1), which encodes FHR1. The mutation resulted in the duplication of the N-terminal short consensus repeats (SCRs) that are conserved in FHR2 and FHR5. We determined that native FHR1, FHR2, and FHR5 circulate in plasma as homo- and hetero-oligomeric complexes, the formation of which is likely mediated by the conserved N-terminal domain. In mutant FHR1, duplication of the N-terminal domain resulted in the formation of unusually large multimeric FHR complexes that exhibited increased avidity for the FHR1 ligands C3b, iC3b, and C3dg and enhanced competition with complement factor H (FH) in surface plasmon resonance (SPR) studies and hemolytic assays. These data revealed that FHR1, FHR2, and FHR5 organize a combinatorial repertoire of oligomeric complexes and demonstrated that changes in FHR oligomerization influence the regulation of complement activation. In summary, our identification and characterization of a unique CFHR1 mutation provides insights into the biology of the FHRs and contributes to our understanding of the pathogenic mechanisms underlying C3G.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23728178      PMCID: PMC3668852          DOI: 10.1172/JCI68280

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

1.  Eculizumab for dense deposit disease and C3 glomerulonephritis.

Authors:  Andrew S Bomback; Richard J Smith; Gaetano R Barile; Yuzhou Zhang; Eliot C Heher; Leal Herlitz; M Barry Stokes; Glen S Markowitz; Vivette D D'Agati; Pietro A Canetta; Jai Radhakrishnan; Gerald B Appel
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-08       Impact factor: 8.237

2.  Eculizumab and refractory membranoproliferative glomerulonephritis.

Authors:  Seetha Radhakrishnan; Andrew Lunn; Michael Kirschfink; Paul Thorner; Diane Hebert; Valerie Langlois; Fred Pluthero; Christoph Licht
Journal:  N Engl J Med       Date:  2012-03-22       Impact factor: 91.245

3.  Functional properties of complement factor H-related proteins FHR-3 and FHR-4: binding to the C3d region of C3b and differential regulation by heparin.

Authors:  J Hellwage; T S Jokiranta; V Koistinen; O Vaarala; S Meri; P F Zipfel
Journal:  FEBS Lett       Date:  1999-12-03       Impact factor: 4.124

4.  Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome.

Authors:  Pilar Sánchez-Corral; David Pérez-Caballero; Olatz Huarte; Ari M Simckes; Elena Goicoechea; Margarita López-Trascasa; Santiago Rodríguez de Córdoba
Journal:  Am J Hum Genet       Date:  2002-11-06       Impact factor: 11.025

5.  Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies.

Authors:  J A McCaughan; D M O'Rourke; A E Courtney
Journal:  Am J Transplant       Date:  2012-01-10       Impact factor: 8.086

6.  Factor H-related protein 4 activates complement by serving as a platform for the assembly of alternative pathway C3 convertase via its interaction with C3b protein.

Authors:  Mario Hebecker; Mihály Józsi
Journal:  J Biol Chem       Date:  2012-04-19       Impact factor: 5.157

7.  Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome.

Authors:  D Pérez-Caballero; C González-Rubio; M E Gallardo; M Vera; M López-Trascasa; S Rodríguez de Córdoba; P Sánchez-Corral
Journal:  Am J Hum Genet       Date:  2001-01-17       Impact factor: 11.025

8.  Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome.

Authors:  Anna Richards; Elizabeth J Kemp; M Kathryn Liszewski; Judith A Goodship; Anne K Lampe; Ronny Decorte; M Hamza Müslümanoğlu; Salih Kavukcu; Guido Filler; Yves Pirson; Leana S Wen; John P Atkinson; Timothy H J Goodship
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-17       Impact factor: 11.205

Review 9.  Complement dysregulation and disease: from genes and proteins to diagnostics and drugs.

Authors:  Santiago Rodriguez de Cordoba; Agustin Tortajada; Claire L Harris; B Paul Morgan
Journal:  Immunobiology       Date:  2012-11       Impact factor: 3.144

10.  Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome.

Authors:  Tamara Manuelian; Jens Hellwage; Seppo Meri; Jessica Caprioli; Marina Noris; Stefan Heinen; Mihaly Jozsi; Hartmut P H Neumann; Giuseppe Remuzzi; Peter F Zipfel
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

View more
  95 in total

Review 1.  CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.

Authors:  Peter F Zipfel; Thorsten Wiech; Emma D Stea; Christine Skerka
Journal:  J Am Soc Nephrol       Date:  2020-01-24       Impact factor: 10.121

2.  Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury.

Authors:  Jennifer Laskowski; Brandon Renner; Moglie Le Quintrec; Sarah Panzer; Jonathan P Hannan; Danica Ljubanovic; Marieta M Ruseva; Dorin-Bogdan Borza; Alexandra H Antonioli; Matthew C Pickering; V Michael Holers; Joshua M Thurman
Journal:  Kidney Int       Date:  2016-05-07       Impact factor: 10.612

Review 3.  C3 Glomerulopathy.

Authors:  Magdalena Riedl; Paul Thorner; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2016-04-07       Impact factor: 3.714

4.  Detection of Genetic Rearrangements in the Regulators of Complement Activation RCA Cluster by High-Throughput Sequencing and MLPA.

Authors:  Jesús García-Fernández; Susana Vilches-Arroyo; Leticia Olavarrieta; Julián Pérez-Pérez; Santiago Rodríguez de Córdoba
Journal:  Methods Mol Biol       Date:  2021

Review 5.  How novel structures inform understanding of complement function.

Authors:  Elena Goicoechea de Jorge; Hugo Yebenes; Marina Serna; Agustín Tortajada; Oscar Llorca; Santiago Rodríguez de Córdoba
Journal:  Semin Immunopathol       Date:  2017-08-14       Impact factor: 9.623

Review 6.  Targeting mechanisms at sites of complement activation for imaging and therapy.

Authors:  V Michael Holers
Journal:  Immunobiology       Date:  2015-04-30       Impact factor: 3.144

7.  Altered Peripheral Blood Leucocyte Phenotype and Responses in Healthy Individuals with Homozygous Deletion of FHR1 and FHR3 Genes.

Authors:  Angika Bhasym; Bahadur Singh Gurjar; Savit Prabhu; Mamta Puraswani; Priyanka Khandelwal; Himanshi Saini; Savita Saini; Priyadarshini Chatterjee; Vineeta Bal; Anna George; Poonam Coshic; Gopal Patidar; Pankaj Hari; Aditi Sinha; Arvind Bagga; Satyajit Rath; Prasenjit Guchhait
Journal:  J Clin Immunol       Date:  2019-04-03       Impact factor: 8.317

Review 8.  Update on membranoproliferative GN.

Authors:  Naveed Masani; Kenar D Jhaveri; Steven Fishbane
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-09       Impact factor: 8.237

Review 9.  The genetics and immunobiology of IgA nephropathy.

Authors:  Krzysztof Kiryluk; Jan Novak
Journal:  J Clin Invest       Date:  2014-06-02       Impact factor: 14.808

Review 10.  All Things Complement.

Authors:  Joshua M Thurman; Carla M Nester
Journal:  Clin J Am Soc Nephrol       Date:  2016-06-23       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.